dc.contributor.author |
Sánchez Rovira, Pedro |
dc.contributor.author |
Seguí, M. A. |
dc.contributor.author |
Llombart, A. |
dc.contributor.author |
Aranda, Enrique |
dc.contributor.author |
Antón, Antonio |
dc.contributor.author |
Sánchez, A. |
dc.contributor.author |
Lomas, M. |
dc.contributor.author |
Jaén, A. |
dc.contributor.author |
Fernández, M. |
dc.contributor.author |
Porras, I. |
dc.contributor.author |
Dalmau, E. |
dc.contributor.author |
Morales Murillo, Serafín |
dc.contributor.author |
Haba-Rodríguez, J. de la |
dc.date |
2021-03-22T09:03:31Z |
dc.date |
2021-03-22T09:03:31Z |
dc.date |
2013 |
dc.identifier |
1699-3055 |
dc.identifier |
http://hdl.handle.net/10459.1/70819 |
dc.identifier |
https://doi.org/10.1007/s12094-013-1006-4 |
dc.identifier.uri |
http://hdl.handle.net/10459.1/70819 |
dc.description |
Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored.
Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment.
Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed.
Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials. |
dc.description |
Financial support for this research was provided by Roche Farma, S.A. |
dc.language |
eng |
dc.publisher |
Springer |
dc.relation |
Reproducció del document publicat a https://doi.org/10.1007/s12094-013-1006-4 |
dc.relation |
Clinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817 |
dc.rights |
cc-by (c) Sánchez-Rovira et al., 2013 |
dc.rights |
http://creativecommons.org/licenses/by/4.0/ |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Bevacizumab |
dc.subject |
Biomarkers |
dc.subject |
Breast cancer |
dc.subject |
Combined modality therapy |
dc.subject |
Neoadjuvant therapy |
dc.title |
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |